Drug Profile
Research programme: atherosclerosis therapy - Trigen
Alternative Names: Anti-inflammatory research programme - Trigen; PR 8Latest Information Update: 16 Apr 2010
Price :
$50
*
At a glance
- Originator Trigen Holdings AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 21 Feb 2008 This programme is still in active development
- 01 Nov 2005 Preclinical trials in Atherosclerosis in United Kingdom (unspecified route)